UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday

UroGen Pharma (NASDAQ:URGN) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The company had revenue of $21.85 million for the quarter, compared to the consensus estimate of $23.69 million. On average, analysts expect UroGen Pharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

UroGen Pharma Stock Performance

Shares of URGN stock opened at $13.02 on Thursday. The firm has a market cap of $305.37 million, a price-to-earnings ratio of -3.83 and a beta of 1.11. The company’s 50 day moving average is $13.03 and its 200 day moving average is $14.28. The company has a quick ratio of 7.93, a current ratio of 8.15 and a debt-to-equity ratio of 3.23. UroGen Pharma has a 52-week low of $10.60 and a 52-week high of $20.70.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on URGN shares. Oppenheimer reissued an “outperform” rating and set a $40.00 price objective on shares of UroGen Pharma in a report on Wednesday, October 16th. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Guggenheim started coverage on shares of UroGen Pharma in a report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday, October 15th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $48.38.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.